Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Rosetta Genomics Expands Management Team

Published: Tuesday, August 26, 2014
Last Updated: Tuesday, August 26, 2014
Bookmark and Share
Brings extensive track record in leading commercial teams and driving revenues in microRNA, oncology and thyroid diagnostics.

Rosetta Genomics Ltd. has announced the appointment of Douglas Sites to the newly-created position of Executive Vice President of Sales and Marketing. Mr. Sites will report to Kenneth A. Berlin, Rosetta's President and Chief Executive Officer.

Mr. Sites joins Rosetta Genomics with more than 25 years of experience in the sales and marketing of medical products, predominantly in diagnostics and laboratory services. Most recently he was Vice President of Sales and Marketing at Asuragen, a high-complexity CLIA laboratory with a focus on microRNA-based diagnostics as well as indeterminate thyroid diagnostics.

"We are delighted to welcome Doug to Rosetta's leadership team. His relevant skillset and depth of experience make him ideally suited to lead our commercial team as we expand Rosetta's commercial capabilities to drive sales of our Cancer of Origin test and prepare for the launch of our microRNA-based thyroid cancer assay, currently in development," stated Mr. Berlin. "As we expand our oncology diagnostic offerings, Doug's insight into both the thyroid and oncology markets, along with his experience building teams, brands and revenues will be invaluable. We look forward to his stewardship of our commercial efforts and are confident he will be an important asset to our team."

"I am excited to be joining the Rosetta Genomics team at this important point in our commercial evolution. With a leadership position in microRNA-based technologies, four marketed cancer diagnostic assays, a promising and diversified pipeline of late-stage product candidates and a talented leadership team, Rosetta holds significant promise to develop into a premier molecular diagnostics company. I look forward to being an instrumental part of Rosetta's growth as we advance our commercial strategy to bring meaningful diagnostics to market to the benefit of the physicians, and ultimately, the patients worldwide," noted Mr. Sites.

Prior to Asuragen, Mr. Sites was Director of Sales-Hematology and Oncology at PLUS Diagnostics, a national anatomical pathology reference laboratory that focuses on hematology oncology physicians. Before that he was with Phenopath Laboratories as Director of Sales and Marketing for this national anatomical pathology reference laboratory that focuses on hospitals, pharmaceutical companies and hematology/oncology markets.

Earlier he was an Anatomic Pathology Specialist at US Labs, Inc., where he designed and developed a selling tool used by the US Lab sales team when competing with in-house immunohistochemistry testing. In addition, Mr. Sites held a number of sales and marketing management positions of increasing responsibility at Ventana Medical Systems, Abbott Diagnostics and McNeil Consumer Products Company, among others. Mr. Sites earned his BA in Business Management and Marketing at The Ohio State University.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rosetta Genomics to Acquire PersonalizeDx
Rosetta will gain proprietary tests in prostate, bladder and lung cancer.
Monday, April 13, 2015
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance
Leverages strengths of both organizations to develop diagnostic assays for important, unmet needs in cancer.
Friday, September 05, 2014
Rosetta Genomics, Moffitt Cancer Center Enter mRNA-Based Cancer Diagnostic Agreement
Partnership to advance the development and commercialization of Rosetta's thyroid neoplasia assay.
Tuesday, June 10, 2014
Rosetta Genomics to Receive U.S. Patent for Oncology Therapeutic
Company receives a Notice of Allowance from the USPTO for a patent claiming Mp53-negative cancer patients.
Thursday, February 27, 2014
Rosetta Genomics Appoints Kevin Watson
Recognized expert in healthcare policy and reimbursement to lead payer efforts for Company's line of microRNA diagnostics.
Thursday, February 20, 2014
Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks
Adds approximately 44 million potential covered lives for the Rosetta Cancer Origin Test.
Monday, September 09, 2013
Study Validating miRview Lung Assay Published in Journal of Molecular Diagnostics
Assay shown to accurately differentiate between the four main types of lung cancer.
Wednesday, July 11, 2012
Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market
Company is in compliance with the $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market®.
Thursday, June 07, 2012
Rosetta to Raise $2.2 Million in Registered Direct Offering
Company has entered into agreements with investors to purchase an aggregate of 632,057 ordinary shares at a price of $3.50 per share.
Friday, May 18, 2012
Rosetta Announces $1.75 Million Debt Financing and Potential $1.25 Million Licensing Transaction
Pursuant to the terms of the transaction, Rosetta has also agreed to negotiate in good faith a definitive license agreement with a designee of the holders of the debentures.
Friday, January 27, 2012
Rosetta Genomics Sells Ownership in Rosetta Green
The diagnostics developer announced that it has entered into a Share Transfer Agreement with certain purchasers, pursuant to which it has sold all of the ordinary shares of Rosetta Green Ltd. ("Rosetta Green") it held.
Monday, December 19, 2011
Rosetta Genomics Announces New York State Approval for miRview mets²
Proprietary microRNA diagnostic for identification of cancer of unknown primary now available in all 50 U.S. states.
Friday, December 09, 2011
microRNAs Shown as Biomarkers for Heart Failure Prognosis
Research shows that elevated serum levels of specific microRNAs identify systolic heart failure (HF) patients and correlate with important clinical prognostic parameters.
Tuesday, November 29, 2011
Rosetta Genomics Announces Changes to Board of Directors
Kenneth A. Berlin, President and CEO of Rosetta Genomics, has stepped down from the Company's Board of Directors.
Monday, April 04, 2011
Rosetta Genomics Receives Grant and Joins Rimonim Pharmaceutical Consortium
Consortium aimed to bring Israeli biotechnology companies together to promote RNAi-based therapeutics which is funded by the Office of the Israeli Chief Scientist.
Wednesday, January 12, 2011
Scientific News
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos